Pemvidutide is currently being evaluated in the phase 2 RECLAIM study, which is enrolling approximately 100 patients with AUD and obesity or overweight.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Computational models of the glucoregulatory system constitute a powerful tool for preclinical evaluation and mechanistic insight into therapeutics. However, in the case of diabetes, there is a dearth ...

Although epinephrine and ACTH were only transiently effective, the intravenous administration of glucagon¶ over a two-and-a-half-month period resulted in a decrease in both . . .

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are also called GLP-1 medications, short for glucagon-like peptide-1 agonists, ...